JP7493521B2 - Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ - Google Patents

Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ Download PDF

Info

Publication number
JP7493521B2
JP7493521B2 JP2021546211A JP2021546211A JP7493521B2 JP 7493521 B2 JP7493521 B2 JP 7493521B2 JP 2021546211 A JP2021546211 A JP 2021546211A JP 2021546211 A JP2021546211 A JP 2021546211A JP 7493521 B2 JP7493521 B2 JP 7493521B2
Authority
JP
Japan
Prior art keywords
day
amino
cancer
pharma
tno155
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021546211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519375A (ja
JPWO2020165734A5 (enExample
Inventor
パン チェン，イン－ナン
ハオ，シュエシャン
リウ，チェン
モーセニ，モーバリッド
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022519375A publication Critical patent/JP2022519375A/ja
Publication of JPWO2020165734A5 publication Critical patent/JPWO2020165734A5/ja
Application granted granted Critical
Publication of JP7493521B2 publication Critical patent/JP7493521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021546211A 2019-02-12 2020-02-10 Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ Active JP7493521B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804708P 2019-02-12 2019-02-12
US62/804,708 2019-02-12
PCT/IB2020/051031 WO2020165734A1 (en) 2019-02-12 2020-02-10 Pharmaceutical combination comprising tno155 and ribociclib

Publications (3)

Publication Number Publication Date
JP2022519375A JP2022519375A (ja) 2022-03-23
JPWO2020165734A5 JPWO2020165734A5 (enExample) 2023-02-17
JP7493521B2 true JP7493521B2 (ja) 2024-05-31

Family

ID=69724013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546211A Active JP7493521B2 (ja) 2019-02-12 2020-02-10 Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ

Country Status (13)

Country Link
US (1) US12343344B2 (enExample)
EP (1) EP3923941B1 (enExample)
JP (1) JP7493521B2 (enExample)
KR (1) KR20210126653A (enExample)
CN (1) CN113382731A (enExample)
AU (3) AU2020222296B2 (enExample)
BR (1) BR112021015632A2 (enExample)
CA (1) CA3127286A1 (enExample)
CL (1) CL2021002099A1 (enExample)
IL (1) IL284835B2 (enExample)
MX (1) MX2021009563A (enExample)
TW (1) TWI831916B (enExample)
WO (1) WO2020165734A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120208856A (zh) 2018-09-29 2025-06-27 诺华股份有限公司 用于抑制shp2活性的化合物和组合物的制造
US12138262B2 (en) 2018-09-29 2024-11-12 Novartis Ag Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
US20220160706A1 (en) * 2019-02-12 2022-05-26 Novartis Ag Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
AU2021293228A1 (en) 2020-06-18 2023-02-09 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
KR20230038197A (ko) 2020-07-08 2023-03-17 노파르티스 아게 Shp2의 활성 억제를 위한 화합물 및 조성물의 제조
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
US20240238284A1 (en) * 2021-05-05 2024-07-18 Novartis Ag Compounds and compositions for the treatment of mpnst
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
US12390469B2 (en) * 2021-05-05 2025-08-19 Huyabio International, Llc SHP2 inhibitor monotherapy and uses thereof
TW202309052A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202342040A (zh) 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
KR20250022133A (ko) 2022-06-10 2025-02-14 레볼루션 메디슨즈, 인크. 거대고리 ras 억제제
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
KR20240097396A (ko) 2022-12-20 2024-06-27 재단법인대구경북과학기술원 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
KR20250169290A (ko) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502993A (ja) 2014-01-17 2017-01-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するためのｎ−アザスピロシクロアルカン置換ｎ−ヘテロアリール化合物および組成物
WO2018130928A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
JP2022519385A (ja) 2019-02-12 2022-03-23 ノバルティス アーゲー Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ
JP2022520079A (ja) 2019-02-12 2022-03-28 ノバルティス アーゲー Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
BR112020004246A2 (pt) * 2017-09-07 2020-09-01 Revolution Medicines, Inc. composições inibidoras de shp2 e métodos para o tratamento de câncer
EP3897659A4 (en) 2018-12-17 2022-09-07 Lunella Biotech, Inc. Triple combination therapies for anti-aging
AU2019403048B2 (en) 2018-12-17 2025-01-23 Lunella Biotech, Inc. Triple combination therapies for targeting mitochondria and killing cancer stem cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502993A (ja) 2014-01-17 2017-01-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するためのｎ−アザスピロシクロアルカン置換ｎ−ヘテロアリール化合物および組成物
WO2018130928A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
JP2022519385A (ja) 2019-02-12 2022-03-23 ノバルティス アーゲー Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ
JP2022520079A (ja) 2019-02-12 2022-03-28 ノバルティス アーゲー Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought，Cancer Cell，2018年，34，pp.9-20，https://doi.org/10.1016/j.ccell.2018.03.023
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors，Clin Cancer Res，2017年，23(13)，pp.3251-3262，doi:10.1158/1078-0432.CCR-16-3157
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models，Oncotarget，2018年，Vol. 9, (No. 81)，pp: 35226-35240

Also Published As

Publication number Publication date
EP3923941A1 (en) 2021-12-22
AU2020222296B2 (en) 2023-04-06
US12343344B2 (en) 2025-07-01
AU2020222296A1 (en) 2021-08-05
CL2021002099A1 (es) 2022-04-18
EP3923941B1 (en) 2025-12-03
CA3127286A1 (en) 2020-08-20
JP2022519375A (ja) 2022-03-23
AU2023203751A1 (en) 2023-07-13
IL284835B1 (en) 2025-04-01
AU2025203816A1 (en) 2025-06-12
WO2020165734A1 (en) 2020-08-20
BR112021015632A2 (pt) 2021-10-05
IL284835B2 (en) 2025-08-01
US20220160707A1 (en) 2022-05-26
MX2021009563A (es) 2021-09-08
KR20210126653A (ko) 2021-10-20
TWI831916B (zh) 2024-02-11
IL284835A (en) 2021-08-31
CN113382731A (zh) 2021-09-10
TW202045171A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
JP7493521B2 (ja) Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ
JP7572958B2 (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
US11564929B2 (en) Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
US11872211B2 (en) Treatments with nirogacestat
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
JP2025094216A (ja) 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
JP2025529199A (ja) がんの治療で使用するためのｄｃｃ－３１１６とｍａｐｋａｐ経路阻害剤との併用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240521

R150 Certificate of patent or registration of utility model

Ref document number: 7493521

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150